Neuren Rights Issue Offer Document (NZ residents)
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Rett Syndrome pre-IND meeting held with FDA
- Neuren to proceed with oral NNZ2566 trial
- Neuren Completes Phase II trial Cohort 2
- Neuren 2011 Preliminary Final Report
- Appendix 4E and Financial Report 31 December 2015
Later from Neuren Pharmaceuticals
- Neuren Completes Phase II trial Cohort 1
- Neuren reduces outstanding convertible note principal
- Neuren Completes Additional Phase I Study for TBI
- Neuren Initiates NNZ2566 Oral Formulation Development
- Cato strategic partnership and appoints US CMO
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals